Clinical trials: MCOS
Melanocortin Obesity Syndrome, MCOS
Atomoxetine in Melanocortin Obesity Syndrome
This is a phase 2 randomized placebo-controlled crossover trial to determine the safety and efficacy of atomoxetine for treating obesity caused by loss-of-function variants in the melanocortin-4 receptor (MC4R), the most common…
- Trial name
- MCOS (NCT06899178)
- Testing
- Atomoxetine
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Icahn School of Medicine at Mount Sinai